Cingulate (CING) FDA Approvals $4.51 -0.75 (-14.26%) Closing price 04:00 PM EasternExtended Trading$4.58 +0.07 (+1.55%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings Cingulate's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Cingulate (CING). Over the past two years, Cingulate has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as CTx-1301. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. CTx-1301 FDA Regulatory Timeline and Events CTx-1301 is a drug developed by Cingulate for the following indication: Attention Deficit/Hyperactivity Disorder (ADHD). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Regulatory Update - November 10,2026Regulatory Update Drug: CTx-1301Announced Date: November 10, 2026Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc. announced today that Chairman and CEO Shane J. Schaffer has provided an update on the regulatory progress of CTx-1301(dexmethylphenidate HCl), the company’s lead asset for the treatment of attention deficit/hyperactivity disorder (ADHD).Read AnnouncementPublication - August 11,2026Publication Drug: CTx-1301Announced Date: August 11, 2026Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc. announced the publication of "Comparative Bioavailability of Trimodal CTx-1301 Versus Bimodal Dexmethylphenidate" in the peer-reviewed journal CNS Drugs.AI SummaryCingulate Inc. announced that its study, “Comparative Bioavailability of Trimodal CTx-1301 Versus Bimodal Dexmethylphenidate,” was published in the peer-reviewed journal CNS Drugs. The open-access paper reports pharmacokinetic and safety results from a randomized crossover study in adults with ADHD. It compared CTx-1301, an investigational once-daily dexmethylphenidate tablet, with a commercially available bimodal formulation. The study found that CTx-1301 produced early drug levels comparable to the comparison product and higher levels later in the dosing period. This pattern is consistent with its design, which releases medication in three timed doses to provide exposure across the active day. Drug levels then declined in a controlled way, intended to limit late-day “wear-off.” Participants also had fewer treatment-emergent adverse events with CTx-1301, despite receiving a higher total dose. The findings add pharmacokinetic evidence about the product’s delivery design; they do not establish that it is approved or available as a treatment.Read AnnouncementComplete Response Letter - June 2,2026Complete Response Letter NDADrug: CTx-1301Announced Date: June 2, 2026Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc. announced that the U.S. Food and Drug Administration ("FDA") has issued a Complete Response Letter for its New Drug Application ("NDA") for CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).AI SummaryCingulate Inc. said the U.S. Food and Drug Administration has issued a Complete Response Letter for its New Drug Application for CTx-1301, a treatment for attention-deficit/hyperactivity disorder (ADHD). The company said the FDA’s feedback was mainly focused on Chemistry, Manufacturing and Controls, or CMC, information requests. Importantly, Cingulate said the agency did not identify any current concerns about the drug’s clinical safety or effectiveness. The company plans to respond quickly and submit the requested information to address the FDA’s questions. Cingulate also noted that it remains financially strong, with nearly $30 million in cash on hand. The company said it is working to move the review process forward as soon as possible.Read AnnouncementPresentation - October 28,2025Presentation Phase 3Drug: CTx-1301Announced Date: October 28, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc. announced today that the positive Phase 3 results from its pivotal trial of CTx-1301 (dexmethylphenidate HCl) in pediatric ADHD, were recently presented by Ann Childress, M.D., at the AACAP Annual Meeting in Chicago. CTx-1301 met its primary endpoint, demonstrating dose-dependent improvements on the ADHD ratings scale 5 (ADHD-RS-5), and Clinical Global Impression-Severity (CGI-S) scales, and demonstrated the ability to deliver symptom relief with the convenience of once-daily dosing.AI SummaryCingulate Inc. announced that positive Phase 3 results for CTx-1301 (dexmethylphenidate HCl) in pediatric ADHD were presented by Ann Childress, M.D., at the AACAP Annual Meeting in Chicago. In this pivotal trial, CTx-1301 met its primary endpoint by showing dose-dependent improvements on the ADHD Rating Scale-5 (ADHD-RS-5) and the Clinical Global Impression-Severity (CGI-S) scale. The study highlighted the ability to deliver reliable symptom relief with once-daily dosing. The randomized, double-blind, placebo-controlled trial in children and adolescents demonstrated a rapid onset of effect and sustained efficacy through the evening hours. Safety and tolerability were in line with other stimulant medications, and no unexpected adverse events were reported. Dr. Childress noted that the 37.5 mg dose produced the largest effect size in symptom reduction, even under forced-dose conditions. She added that the safety profile resembled that of existing methylphenidate products, with no new concerns. By offering effective, once-daily relief, CTx-1301 could simplify ADHD management and improve adherence for patients and their families.Read AnnouncementData - October 23,2025Data Drug: CTx-1301Announced Date: October 23, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc announced that data from its lead ADHD candidate CTx-1301 (dexmethylphenidate HCl) has been selected for podium presentation at the American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting in Chicago.AI SummaryCingulate Inc. announced that data from its lead ADHD treatment, CTx-1301 (dexmethylphenidate HCl), was selected for a podium presentation at the American Academy of Child and Adolescent Psychiatry Annual Meeting in Chicago. The meeting is a top event for child and adolescent psychiatry. The data come from a Phase 3 trial of CTx-1301, a once-daily, extended-release tablet designed to give rapid symptom relief and full-day coverage. Dr. Ann Childress, a renowned ADHD specialist, will present the findings on October 24, 2025, under the title “Efficacy and Safety of CTx-1301 in Pediatric Subjects With ADHD.” Dr. Childress said the trial results offer valuable insights into how CTx-1301 can simplify treatment with convenient once-daily dosing. Raul Silva, Chief Science Officer at Cingulate, added that selection for an AACAP podium highlights the rigorous science behind the therapy and its potential to overcome current stimulant limitations like delayed onset and inconsistent duration.Read AnnouncementPDUFA Date - October 14,2025Pdufa Date NDADrug: CTx-1301Announced Date: October 14, 2025Target Action Date: May 31, 2026Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc. announced that The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026.AI SummaryCingulate Inc. is developing CTx-1301, a once-daily stimulant tablet for treating ADHD in children and adults. The drug uses the company’s Precision Timed Release™ (PTR™) platform to deliver three timed doses of dexmethylphenidate, aiming to provide fast symptom relief and coverage throughout the day. The U.S. Food and Drug Administration has set a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026, for CTx-1301. The application is being reviewed under the 505(b)(2) pathway, which lets Cingulate leverage existing safety data on dexmethylphenidate while presenting its novel drug-delivery design. This PDUFA date marks a crucial regulatory milestone for Cingulate. If approved, CTx-1301 could address common ADHD treatment gaps—like midday symptom rebound and dosing challenges—and support the company’s transition toward commercialization and supplying a new, patient-friendly option in 2026.Read Announcementreview - October 14,2025Review NDADrug: CTx-1301Announced Date: October 14, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for CTx-1301 (dexmethylphenidate), the company's lead candidate for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adults.AI SummaryCingulate Inc. announced that the U.S. Food and Drug Administration has accepted for review its New Drug Application for CTx-1301, a once-daily precision timed-release stimulant designed to treat ADHD in children and adults. CTx-1301 uses a multi-core tablet to deliver rapid symptom relief and maintain effect throughout the active day. The application was filed under the FDA’s 505(b)(2) pathway, allowing Cingulate to reference existing dexmethylphenidate data while showing the novel benefits of its delivery system. The FDA set a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026. Acceptance of the NDA means the submission is complete and ready for full review. CTx-1301 completed adult and pediatric Phase 3 trials, showing large improvements in key ADHD measures and no serious treatment-related adverse events. With formal review now underway, Cingulate is preparing for a potential 2026 commercial launch pending approval.Read AnnouncementNDA Filing - August 6,2025Nda Filing Drug: CTx-1301Announced Date: August 6, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for CTx-1301(dexmethylphenidate HCl), the company's lead asset for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).AI SummaryCingulate Inc. announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for CTx-1301 (dexmethylphenidate HCl), its leading treatment for Attention Deficit/Hyperactivity Disorder (ADHD). This marks a key milestone for the company as it moves toward potential U.S. approval. CTx-1301 is a novel, extended-release tablet that uses Cingulate’s Precision Timed Release™ platform. It is designed to deliver a quick start, all-day symptom control, and a smooth drug profile with just one daily dose. The goal is to address gaps in current ADHD therapies, such as uneven effect and multiple daily dosing. Cingulate expects to learn within 60 days whether the FDA has accepted the NDA for review. Company leaders believe CTx-1301 could improve patient outcomes across ages and capture significant share in the $23 billion U.S. ADHD market if approved.Read AnnouncementProvided Update - July 29,2025Provided Update NDADrug: CTx-1301Announced Date: July 29, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc. announced that it has received a fiscal year 2025 PDUFA (Prescription Drug User Fee Act) fee waiver from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) for lead asset CTx-1301 (dexmethylphenidate HCI) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).AI SummaryCingulate Inc. announced it has received a fiscal year 2025 PDUFA fee waiver from the U.S. Food and Drug Administration for its new drug application (NDA) for CTx-1301 (dexmethylphenidate HCl), an ADHD treatment. This waiver was granted under the small business provision of the Federal Food, Drug, and Cosmetic Act. The waiver will save Cingulate approximately $4.3 million as the company finalizes its NDA submission at the end of the month. CTx-1301 uses Cingulate’s Precision Timed Release™ (PTR™) platform to deliver three precise doses of dexmethylphenidate in one tablet. This design aims to provide rapid onset and full-day symptom control with a single daily pill. “We are pleased to receive this significant waiver as we approach the submission of our NDA and look forward to continuing to work with the FDA throughout the review process,” said Cingulate CEO Shane J. Schaffer. He added that the fee savings will strengthen the company’s financial position as it prepares to commercialize CTx-1301.Read AnnouncementEfficacy Data - May 20,2025Efficacy Data Phase 3Drug: CTx-1301Announced Date: May 20, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate announced the efficacy results from an FDA required Phase 3, randomized, fixed dose, double blind, placebo controlled clinical study in pediatrics (aged 6-17), for its lead asset CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).AI SummaryCingulate Inc. announced positive efficacy results from an FDA-required Phase 3 clinical study evaluating its lead asset, CTx‑1301 (dexmethylphenidate HCl), for treating ADHD in pediatric patients aged 6–17. This randomized, fixed-dose, double-blind, and placebo-controlled study used fixed doses of 18.75 mg, 25 mg, and 37.5 mg. Within five weeks, subjects in all dose groups showed statistically significant improvements in ADHD symptoms, as measured by the ADHD‑RS‑5 rating scale. Effect sizes ranged from 0.737 at the lowest dose to 1.185 at the highest dose, demonstrating robust efficacy. If approved by the FDA, CTx‑1301 is expected to become an important treatment option for ADHD, addressing longstanding unmet needs. The study’s positive findings underscore the potential of Cingulate’s innovative Precision Timed Release drug delivery platform to offer reliable, once-daily dosing for pediatric patients.Read AnnouncementMeeting minutes - May 14,2025Meeting Minutes pre-New Drug Application (NDA)Drug: CTx-1301Announced Date: May 14, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc. announced that it has received formal pre-New Drug Application (NDA) meeting minutes from the U.S. Food and Drug Administration (FDA) for it's lead asset CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).AI SummaryCingulate Inc. recently announced that it has received formal pre-New Drug Application (NDA) meeting minutes from the U.S. Food and Drug Administration (FDA) for its lead asset, CTx-1301 (dexmethylphenidate), intended for treating Attention Deficit/Hyperactivity Disorder (ADHD). The FDA’s minutes provided feedback that aligns with Cingulate’s plans to file its NDA this summer. In these discussions, the FDA agreed to a post-NDA commitment to collect additional stability data for six intermediate dose strengths and noted that current nonclinical safety data is adequate to support a filing. Furthermore, it found the company’s proposed approach to the integrated safety and efficacy summaries reasonable. CTx-1301 utilizes a Precision Timed Release technology that aims to deliver medication in three timed releases, providing a full day of symptom control, and positioning the drug as the first true once-daily stimulant for ADHD. Read AnnouncementTop-line results - April 29,2025Top-Line Results Drug: CTx-1301Announced Date: April 29, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc announced positive top-line results from the CTx-1301-013 study, an FDA required study, assessing the effect of food on absorption of the highest dose (50mg) of its lead candidate CTx-1301.AI SummaryCingulate Inc. announced positive top-line results from its FDA-required CTx-1301-013 study, which evaluated whether food affects the absorption of its highest 50mg dose of CTx-1301, a novel treatment for ADHD. The study involved 27 healthy adults who received the medication both with a standard high-fat breakfast and on an empty stomach. Key pharmacokinetic measurements—including the peak plasma concentration and the overall drug exposure—demonstrated that food does not impact the absorption of the 50mg dose. This means that CTx-1301 can be taken with or without food, offering simplicity and consistency in dosing. The results confirm that the formulation of 50mg CTx-1301 is optimal for providing full-day coverage for ADHD symptoms. These findings support further development and future presentations, with hopes of improving ADHD management through a true once-daily stimulant treatment.Read AnnouncementPre-IND Meeting - April 3,2025Pre-Ind Meeting NDADrug: CTx-1301Announced Date: April 3, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate announced that it held a Pre-NDA meeting with the U.S. Food and Drug Administration (FDA) yesterday to discuss the submission of a new drug application (NDA) for its lead Phase 3 asset CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).AI SummaryCingulate Inc. held a Pre-NDA meeting with the U.S. Food and Drug Administration (FDA) to discuss its upcoming submission of a new drug application (NDA) for its lead Phase 3 product, CTx-1301 (dexmethylphenidate HCl), which is intended to treat Attention Deficit/Hyperactivity Disorder (ADHD). The company, known for its proprietary Precision Timed Release (PTR™) drug delivery platform, reported that the meeting was very productive. During the discussions, the FDA provided valuable insights that will guide the NDA filing planned for mid-2025. This milestone reinforces Cingulate’s mission to introduce the first true once-daily stimulant medication designed to offer therapeutic benefits throughout the active day, potentially improving treatment outcomes for ADHD patients.Read AnnouncementSafety Data - March 4,2025Safety Data Phase 3Drug: CTx-1301Announced Date: March 4, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc today released Phase 3 safety data for its lead asset CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).AI SummaryCingulate Inc has released Phase 3 safety data for its lead asset, CTx-1301 (dexmethylphenidate), a novel once-daily stimulant designed to treat ADHD throughout the active day. The data comes from two pediatric and adolescent trials—a fixed dose study and a dose optimization study—as well as a separate food effect study in healthy adults using a 50mg dose. The comprehensive results demonstrate a stable safety profile with no serious adverse events or treatment-related deaths. Importantly, the studies confirmed that CTx-1301 can be taken with or without food while providing continuous therapeutic effects, potentially reducing the need for additional dosing and lowering risks such as crashes or rebound symptoms. The safety findings, consistent across multiple trials, have been submitted to the FDA ahead of an in-person Pre-NDA meeting scheduled for April 2, 2025, paving the way for the product’s upcoming new drug application submission.Read AnnouncementNDA Filing - January 7,2025Nda Filing NDADrug: CTx-1301Announced Date: January 7, 2025Target Action Date: H1 2025Estimated Target Date Range: January 1, 2025 - June 30, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc announced that Submission of New Drug Application Targeted for Mid 2025AI SummaryCingulate Inc announced that it has completed the final FDA-required food effect study for its lead drug candidate, CTx-1301, designed to treat ADHD. In this study, 26 healthy adults received a single 50mg dose in both fed and fasted states, and no serious adverse events were reported. The trial is a key step to verify that the medication works effectively regardless of food intake by checking how it is absorbed in the body. The successful completion of this study is one of the last steps before Cingulate submits a New Drug Application (NDA) to the FDA, a submission they are targeting for mid-2025. The company’s approach aims to provide a once-daily stimulant medication with a full active-day duration using its Precision Timed Release (PTR) platform.Read AnnouncementStudy completion - January 7,2025Study Completion Drug: CTx-1301Announced Date: January 7, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc announced that it has completed its final FDA-required study, which is a food effect study, for CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).AI SummaryCingulate Inc. announced that it has completed its final FDA-required food effect study for CTx‑1301 (dexmethylphenidate), their lead candidate for treating Attention Deficit Hyperactivity Disorder (ADHD). The study tested a single 50mg dose of CTx‑1301 in healthy subjects under fed and fasted conditions. The aim was to determine whether food impacts the absorption and bioavailability of the medication. Results showed that there were no serious adverse events, indicating that CTx‑1301 could be safely taken with or without food. A detailed data readout regarding bioavailability is expected in the second quarter of 2025. This milestone is a significant step as the company finalizes the necessary clinical activities for its New Drug Application (NDA) submission to the FDA, which is targeted for mid‑2025.Read Announcement Cingulate FDA Events - Frequently Asked Questions Has Cingulate received FDA approval? As of now, Cingulate (CING) has not received any FDA approvals for its therapy in the last two years. What drugs has Cingulate submitted to the FDA? In the past two years, Cingulate (CING) has reported FDA regulatory activity for CTx-1301. What is the most recent FDA event for Cingulate? The most recent FDA-related event for Cingulate occurred on November 10, 2026, involving CTx-1301. The update was categorized as "Regulatory Update," with the company reporting: "Cingulate Inc. announced today that Chairman and CEO Shane J. Schaffer has provided an update on the regulatory progress of CTx-1301(dexmethylphenidate HCl), the company’s lead asset for the treatment of attention deficit/hyperactivity disorder (ADHD)." What conditions do Cingulate's current drugs treat? Currently, Cingulate has one therapy (CTx-1301) targeting the following condition: Attention Deficit/Hyperactivity Disorder (ADHD). More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Belite Bio FDA EventsErasca FDA EventsGilead Sciences FDA EventsNuCana FDA EventsUnited Therapeutics FDA EventsAdagene FDA EventsAlnylam Pharmaceuticals FDA EventsGE HealthCare Technologies FDA EventsGenprex FDA EventsHUTCHMED FDA EventsOpus Genetics FDA EventsLigand Pharmaceuticals FDA EventsEthos Technologies Inc. Class A Common Stock FDA EventsRegeneron Pharmaceuticals FDA EventsTvardi Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Amarin FDA Events Vanda Pharmaceuticals FDA Events Bright Minds Biosciences FDA Events Inhibikase Therapeutics FDA Events Sol-Gel Technologies FDA Events Palisade Bio FDA Events Jyong Biotech FDA Events Zentalis Pharmaceuticals FDA Events Journey Medical FDA Events PolyPid FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:CING last updated on 11/10/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredBlack Friday Special: Buy These Stocks Before Nov. 30thKeith Kaplan's firm has invested $17 million in its own AI research and tools, and 180,000 people worldwide no...TradeSmith | SponsoredWashington's deadline. Elon's problem.On January 1, 2027, Washington raises the outside-China sourcing requirement for grid battery projects seeking...Behind the Markets | SponsoredThe One-Ticker Retirement BoostA $10,000 investment at its 1998 start would be worth over $630,000 today, roughly 6X the S&P 500 over the sam...The Oxford Club | SponsoredShould I sell? $84 off ends Dec 9A stock you own drops 20%, and you're asking yourself: should I sell? Seeking Alpha Premium gives you a second...Seeking Alpha | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Regulatory Update - November 10,2026Regulatory Update Drug: CTx-1301Announced Date: November 10, 2026Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc. announced today that Chairman and CEO Shane J. Schaffer has provided an update on the regulatory progress of CTx-1301(dexmethylphenidate HCl), the company’s lead asset for the treatment of attention deficit/hyperactivity disorder (ADHD).Read Announcement
Publication - August 11,2026Publication Drug: CTx-1301Announced Date: August 11, 2026Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc. announced the publication of "Comparative Bioavailability of Trimodal CTx-1301 Versus Bimodal Dexmethylphenidate" in the peer-reviewed journal CNS Drugs.AI SummaryCingulate Inc. announced that its study, “Comparative Bioavailability of Trimodal CTx-1301 Versus Bimodal Dexmethylphenidate,” was published in the peer-reviewed journal CNS Drugs. The open-access paper reports pharmacokinetic and safety results from a randomized crossover study in adults with ADHD. It compared CTx-1301, an investigational once-daily dexmethylphenidate tablet, with a commercially available bimodal formulation. The study found that CTx-1301 produced early drug levels comparable to the comparison product and higher levels later in the dosing period. This pattern is consistent with its design, which releases medication in three timed doses to provide exposure across the active day. Drug levels then declined in a controlled way, intended to limit late-day “wear-off.” Participants also had fewer treatment-emergent adverse events with CTx-1301, despite receiving a higher total dose. The findings add pharmacokinetic evidence about the product’s delivery design; they do not establish that it is approved or available as a treatment.Read Announcement
Complete Response Letter - June 2,2026Complete Response Letter NDADrug: CTx-1301Announced Date: June 2, 2026Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc. announced that the U.S. Food and Drug Administration ("FDA") has issued a Complete Response Letter for its New Drug Application ("NDA") for CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).AI SummaryCingulate Inc. said the U.S. Food and Drug Administration has issued a Complete Response Letter for its New Drug Application for CTx-1301, a treatment for attention-deficit/hyperactivity disorder (ADHD). The company said the FDA’s feedback was mainly focused on Chemistry, Manufacturing and Controls, or CMC, information requests. Importantly, Cingulate said the agency did not identify any current concerns about the drug’s clinical safety or effectiveness. The company plans to respond quickly and submit the requested information to address the FDA’s questions. Cingulate also noted that it remains financially strong, with nearly $30 million in cash on hand. The company said it is working to move the review process forward as soon as possible.Read Announcement
Presentation - October 28,2025Presentation Phase 3Drug: CTx-1301Announced Date: October 28, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc. announced today that the positive Phase 3 results from its pivotal trial of CTx-1301 (dexmethylphenidate HCl) in pediatric ADHD, were recently presented by Ann Childress, M.D., at the AACAP Annual Meeting in Chicago. CTx-1301 met its primary endpoint, demonstrating dose-dependent improvements on the ADHD ratings scale 5 (ADHD-RS-5), and Clinical Global Impression-Severity (CGI-S) scales, and demonstrated the ability to deliver symptom relief with the convenience of once-daily dosing.AI SummaryCingulate Inc. announced that positive Phase 3 results for CTx-1301 (dexmethylphenidate HCl) in pediatric ADHD were presented by Ann Childress, M.D., at the AACAP Annual Meeting in Chicago. In this pivotal trial, CTx-1301 met its primary endpoint by showing dose-dependent improvements on the ADHD Rating Scale-5 (ADHD-RS-5) and the Clinical Global Impression-Severity (CGI-S) scale. The study highlighted the ability to deliver reliable symptom relief with once-daily dosing. The randomized, double-blind, placebo-controlled trial in children and adolescents demonstrated a rapid onset of effect and sustained efficacy through the evening hours. Safety and tolerability were in line with other stimulant medications, and no unexpected adverse events were reported. Dr. Childress noted that the 37.5 mg dose produced the largest effect size in symptom reduction, even under forced-dose conditions. She added that the safety profile resembled that of existing methylphenidate products, with no new concerns. By offering effective, once-daily relief, CTx-1301 could simplify ADHD management and improve adherence for patients and their families.Read Announcement
Data - October 23,2025Data Drug: CTx-1301Announced Date: October 23, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc announced that data from its lead ADHD candidate CTx-1301 (dexmethylphenidate HCl) has been selected for podium presentation at the American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting in Chicago.AI SummaryCingulate Inc. announced that data from its lead ADHD treatment, CTx-1301 (dexmethylphenidate HCl), was selected for a podium presentation at the American Academy of Child and Adolescent Psychiatry Annual Meeting in Chicago. The meeting is a top event for child and adolescent psychiatry. The data come from a Phase 3 trial of CTx-1301, a once-daily, extended-release tablet designed to give rapid symptom relief and full-day coverage. Dr. Ann Childress, a renowned ADHD specialist, will present the findings on October 24, 2025, under the title “Efficacy and Safety of CTx-1301 in Pediatric Subjects With ADHD.” Dr. Childress said the trial results offer valuable insights into how CTx-1301 can simplify treatment with convenient once-daily dosing. Raul Silva, Chief Science Officer at Cingulate, added that selection for an AACAP podium highlights the rigorous science behind the therapy and its potential to overcome current stimulant limitations like delayed onset and inconsistent duration.Read Announcement
PDUFA Date - October 14,2025Pdufa Date NDADrug: CTx-1301Announced Date: October 14, 2025Target Action Date: May 31, 2026Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc. announced that The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026.AI SummaryCingulate Inc. is developing CTx-1301, a once-daily stimulant tablet for treating ADHD in children and adults. The drug uses the company’s Precision Timed Release™ (PTR™) platform to deliver three timed doses of dexmethylphenidate, aiming to provide fast symptom relief and coverage throughout the day. The U.S. Food and Drug Administration has set a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026, for CTx-1301. The application is being reviewed under the 505(b)(2) pathway, which lets Cingulate leverage existing safety data on dexmethylphenidate while presenting its novel drug-delivery design. This PDUFA date marks a crucial regulatory milestone for Cingulate. If approved, CTx-1301 could address common ADHD treatment gaps—like midday symptom rebound and dosing challenges—and support the company’s transition toward commercialization and supplying a new, patient-friendly option in 2026.Read Announcement
review - October 14,2025Review NDADrug: CTx-1301Announced Date: October 14, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for CTx-1301 (dexmethylphenidate), the company's lead candidate for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adults.AI SummaryCingulate Inc. announced that the U.S. Food and Drug Administration has accepted for review its New Drug Application for CTx-1301, a once-daily precision timed-release stimulant designed to treat ADHD in children and adults. CTx-1301 uses a multi-core tablet to deliver rapid symptom relief and maintain effect throughout the active day. The application was filed under the FDA’s 505(b)(2) pathway, allowing Cingulate to reference existing dexmethylphenidate data while showing the novel benefits of its delivery system. The FDA set a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026. Acceptance of the NDA means the submission is complete and ready for full review. CTx-1301 completed adult and pediatric Phase 3 trials, showing large improvements in key ADHD measures and no serious treatment-related adverse events. With formal review now underway, Cingulate is preparing for a potential 2026 commercial launch pending approval.Read Announcement
NDA Filing - August 6,2025Nda Filing Drug: CTx-1301Announced Date: August 6, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for CTx-1301(dexmethylphenidate HCl), the company's lead asset for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).AI SummaryCingulate Inc. announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for CTx-1301 (dexmethylphenidate HCl), its leading treatment for Attention Deficit/Hyperactivity Disorder (ADHD). This marks a key milestone for the company as it moves toward potential U.S. approval. CTx-1301 is a novel, extended-release tablet that uses Cingulate’s Precision Timed Release™ platform. It is designed to deliver a quick start, all-day symptom control, and a smooth drug profile with just one daily dose. The goal is to address gaps in current ADHD therapies, such as uneven effect and multiple daily dosing. Cingulate expects to learn within 60 days whether the FDA has accepted the NDA for review. Company leaders believe CTx-1301 could improve patient outcomes across ages and capture significant share in the $23 billion U.S. ADHD market if approved.Read Announcement
Provided Update - July 29,2025Provided Update NDADrug: CTx-1301Announced Date: July 29, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc. announced that it has received a fiscal year 2025 PDUFA (Prescription Drug User Fee Act) fee waiver from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) for lead asset CTx-1301 (dexmethylphenidate HCI) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).AI SummaryCingulate Inc. announced it has received a fiscal year 2025 PDUFA fee waiver from the U.S. Food and Drug Administration for its new drug application (NDA) for CTx-1301 (dexmethylphenidate HCl), an ADHD treatment. This waiver was granted under the small business provision of the Federal Food, Drug, and Cosmetic Act. The waiver will save Cingulate approximately $4.3 million as the company finalizes its NDA submission at the end of the month. CTx-1301 uses Cingulate’s Precision Timed Release™ (PTR™) platform to deliver three precise doses of dexmethylphenidate in one tablet. This design aims to provide rapid onset and full-day symptom control with a single daily pill. “We are pleased to receive this significant waiver as we approach the submission of our NDA and look forward to continuing to work with the FDA throughout the review process,” said Cingulate CEO Shane J. Schaffer. He added that the fee savings will strengthen the company’s financial position as it prepares to commercialize CTx-1301.Read Announcement
Efficacy Data - May 20,2025Efficacy Data Phase 3Drug: CTx-1301Announced Date: May 20, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate announced the efficacy results from an FDA required Phase 3, randomized, fixed dose, double blind, placebo controlled clinical study in pediatrics (aged 6-17), for its lead asset CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).AI SummaryCingulate Inc. announced positive efficacy results from an FDA-required Phase 3 clinical study evaluating its lead asset, CTx‑1301 (dexmethylphenidate HCl), for treating ADHD in pediatric patients aged 6–17. This randomized, fixed-dose, double-blind, and placebo-controlled study used fixed doses of 18.75 mg, 25 mg, and 37.5 mg. Within five weeks, subjects in all dose groups showed statistically significant improvements in ADHD symptoms, as measured by the ADHD‑RS‑5 rating scale. Effect sizes ranged from 0.737 at the lowest dose to 1.185 at the highest dose, demonstrating robust efficacy. If approved by the FDA, CTx‑1301 is expected to become an important treatment option for ADHD, addressing longstanding unmet needs. The study’s positive findings underscore the potential of Cingulate’s innovative Precision Timed Release drug delivery platform to offer reliable, once-daily dosing for pediatric patients.Read Announcement
Meeting minutes - May 14,2025Meeting Minutes pre-New Drug Application (NDA)Drug: CTx-1301Announced Date: May 14, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc. announced that it has received formal pre-New Drug Application (NDA) meeting minutes from the U.S. Food and Drug Administration (FDA) for it's lead asset CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).AI SummaryCingulate Inc. recently announced that it has received formal pre-New Drug Application (NDA) meeting minutes from the U.S. Food and Drug Administration (FDA) for its lead asset, CTx-1301 (dexmethylphenidate), intended for treating Attention Deficit/Hyperactivity Disorder (ADHD). The FDA’s minutes provided feedback that aligns with Cingulate’s plans to file its NDA this summer. In these discussions, the FDA agreed to a post-NDA commitment to collect additional stability data for six intermediate dose strengths and noted that current nonclinical safety data is adequate to support a filing. Furthermore, it found the company’s proposed approach to the integrated safety and efficacy summaries reasonable. CTx-1301 utilizes a Precision Timed Release technology that aims to deliver medication in three timed releases, providing a full day of symptom control, and positioning the drug as the first true once-daily stimulant for ADHD. Read Announcement
Top-line results - April 29,2025Top-Line Results Drug: CTx-1301Announced Date: April 29, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc announced positive top-line results from the CTx-1301-013 study, an FDA required study, assessing the effect of food on absorption of the highest dose (50mg) of its lead candidate CTx-1301.AI SummaryCingulate Inc. announced positive top-line results from its FDA-required CTx-1301-013 study, which evaluated whether food affects the absorption of its highest 50mg dose of CTx-1301, a novel treatment for ADHD. The study involved 27 healthy adults who received the medication both with a standard high-fat breakfast and on an empty stomach. Key pharmacokinetic measurements—including the peak plasma concentration and the overall drug exposure—demonstrated that food does not impact the absorption of the 50mg dose. This means that CTx-1301 can be taken with or without food, offering simplicity and consistency in dosing. The results confirm that the formulation of 50mg CTx-1301 is optimal for providing full-day coverage for ADHD symptoms. These findings support further development and future presentations, with hopes of improving ADHD management through a true once-daily stimulant treatment.Read Announcement
Pre-IND Meeting - April 3,2025Pre-Ind Meeting NDADrug: CTx-1301Announced Date: April 3, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate announced that it held a Pre-NDA meeting with the U.S. Food and Drug Administration (FDA) yesterday to discuss the submission of a new drug application (NDA) for its lead Phase 3 asset CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).AI SummaryCingulate Inc. held a Pre-NDA meeting with the U.S. Food and Drug Administration (FDA) to discuss its upcoming submission of a new drug application (NDA) for its lead Phase 3 product, CTx-1301 (dexmethylphenidate HCl), which is intended to treat Attention Deficit/Hyperactivity Disorder (ADHD). The company, known for its proprietary Precision Timed Release (PTR™) drug delivery platform, reported that the meeting was very productive. During the discussions, the FDA provided valuable insights that will guide the NDA filing planned for mid-2025. This milestone reinforces Cingulate’s mission to introduce the first true once-daily stimulant medication designed to offer therapeutic benefits throughout the active day, potentially improving treatment outcomes for ADHD patients.Read Announcement
Safety Data - March 4,2025Safety Data Phase 3Drug: CTx-1301Announced Date: March 4, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc today released Phase 3 safety data for its lead asset CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).AI SummaryCingulate Inc has released Phase 3 safety data for its lead asset, CTx-1301 (dexmethylphenidate), a novel once-daily stimulant designed to treat ADHD throughout the active day. The data comes from two pediatric and adolescent trials—a fixed dose study and a dose optimization study—as well as a separate food effect study in healthy adults using a 50mg dose. The comprehensive results demonstrate a stable safety profile with no serious adverse events or treatment-related deaths. Importantly, the studies confirmed that CTx-1301 can be taken with or without food while providing continuous therapeutic effects, potentially reducing the need for additional dosing and lowering risks such as crashes or rebound symptoms. The safety findings, consistent across multiple trials, have been submitted to the FDA ahead of an in-person Pre-NDA meeting scheduled for April 2, 2025, paving the way for the product’s upcoming new drug application submission.Read Announcement
NDA Filing - January 7,2025Nda Filing NDADrug: CTx-1301Announced Date: January 7, 2025Target Action Date: H1 2025Estimated Target Date Range: January 1, 2025 - June 30, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc announced that Submission of New Drug Application Targeted for Mid 2025AI SummaryCingulate Inc announced that it has completed the final FDA-required food effect study for its lead drug candidate, CTx-1301, designed to treat ADHD. In this study, 26 healthy adults received a single 50mg dose in both fed and fasted states, and no serious adverse events were reported. The trial is a key step to verify that the medication works effectively regardless of food intake by checking how it is absorbed in the body. The successful completion of this study is one of the last steps before Cingulate submits a New Drug Application (NDA) to the FDA, a submission they are targeting for mid-2025. The company’s approach aims to provide a once-daily stimulant medication with a full active-day duration using its Precision Timed Release (PTR) platform.Read Announcement
Study completion - January 7,2025Study Completion Drug: CTx-1301Announced Date: January 7, 2025Indication: Attention Deficit/Hyperactivity Disorder (ADHD)AnnouncementCingulate Inc announced that it has completed its final FDA-required study, which is a food effect study, for CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).AI SummaryCingulate Inc. announced that it has completed its final FDA-required food effect study for CTx‑1301 (dexmethylphenidate), their lead candidate for treating Attention Deficit Hyperactivity Disorder (ADHD). The study tested a single 50mg dose of CTx‑1301 in healthy subjects under fed and fasted conditions. The aim was to determine whether food impacts the absorption and bioavailability of the medication. Results showed that there were no serious adverse events, indicating that CTx‑1301 could be safely taken with or without food. A detailed data readout regarding bioavailability is expected in the second quarter of 2025. This milestone is a significant step as the company finalizes the necessary clinical activities for its New Drug Application (NDA) submission to the FDA, which is targeted for mid‑2025.Read Announcement